Promising clinical outcomes of sequential and 'Sandwich' chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage IE /IIE extranodal natural killer/T-cell lymphoma

Autor: Hanyu Wang, Yi yang Li, Yun-Ying Yang, Yujing Zhang, Shaoqing Niu, Hong-Bo Chen
Rok vydání: 2018
Předmět:
Adult
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Adolescent
sequential chemoradiotherapy
medicine.medical_treatment
nasal‐type
Antineoplastic Agents
Drug Administration Schedule
extranodal natural killer/T‐cell lymphoma
Young Adult
03 medical and health sciences
0302 clinical medicine
extended involved‐field intensity‐modulated radiotherapy
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Radiology
Nuclear Medicine and imaging
In patient
Stage (cooking)
Original Research
Aged
loco‐regional recurrence
Univariate analysis
Chemotherapy
business.industry
Clinical Cancer Research
Middle Aged
medicine.disease
Natural killer T cell
Combined Modality Therapy
Primary tumor
Lymphoma
Lymphoma
Extranodal NK-T-Cell
Radiation therapy
Treatment Outcome
030104 developmental biology
030220 oncology & carcinogenesis
Female
prognosis
Radiotherapy
Intensity-Modulated
business
Zdroj: Cancer Medicine
ISSN: 2045-7634
DOI: 10.1002/cam4.1755
Popis: Background The optimal treatment for the rare subtype of non‐Hodgkin lymphoma, extranodal natural killer/T‐cell lymphoma (ENKTL), nasal‐type, has not been clearly defined. The purpose of the study was to investigate the efficacy of sequential and “Sandwich” chemotherapy and extended involved‐field intensity‐modulated radiotherapy (IMRT) in patients with stage IE/IIE extranodal ENKTL, nasal‐type. Methods One hundred and fifty‐five patients with stage IE/IIE nasal‐type ENKTL were enrolled in the study, including 99 patients treated with sequential chemotherapy and extended involved‐field IMRT (SCRT) and 56 patients with “Sandwich” chemotherapy and extended involved‐field IMRT and chemotherapy (SCRCT). All patients were treated with extended involved‐field IMRT with median dose of 54.6 Gy to the primary tumor and positive lymph nodes. Ninety‐four patients had Ann Arbor stage IE disease, and 61 patients had stage IIE disease. Results The 5‐year rates of loco‐regional recurrence (LRR), progression‐free survival (PFS), and overall survival (OS) were 17.0%, 78.5%, and 84.7%, respectively. Univariate analysis revealed that EBV DNA copy after treatment (normal vs elevated level) was significant prognostic factor for LRR, PFS, and OS (P
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje